Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

Clear Street starts Q32 Bio at buy; PT $38

Clear Street initiated coverage of Q32 Bio (NASDAQ: QTTB) with a “buy” rating and price target of $38.00. The stock closed at $8.77 on September 25. Q32 Bio is a clinical-stage biotechnology company developing therapies...

September 28, 2026

Markets

Lucid starts Lensar at buy; PT $11

Lucid Capital Markets initiated coverage of Lensar (NASDAQ: LNSR) with a “buy” rating and price target of $11.00. The stock closed at $6.92 on September 25. Lensar designs, manufactures, and commercializes femtosecond...

September 28, 2026

Developments

Codexis enters agreement with drug innovator to create stereo-defined siRNA

Codexis (NASDAQ: CDXS) has announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis Manufacturing Platform. According to Codexis, the agreement...

September 28, 2026

Developments

DataMeds AI and Tollo Health announce mobile app

DataMeds AI (NASDAQ: MEDS) and closely held Tollo Health have announced the launch of the Health Lives Here mobile application (app), initially focused on supporting users of GLP-1 receptor agonist medications...

September 28, 2026

Developments

Firefly and NeuroSigma partner to expand access to first FDA-cleared non-drug for pediatric ADHD

Firefly Neuroscience (NASDAQ: AIFF) has announced a strategic partnership to expand clinician awareness of and access to NeuroSigma’s Monarch eTNS System, the first FDA-cleared non-drug for pediatric attention...

September 25, 2026

Developments

NeuroThera expands IP portfolio through collaboration with Clearmind

NeuroThera Labs (TSXV: NTLX) has highlighted the expansion of the U.S. intellectual property (IP) portfolio through its ongoing collaboration with Clearmind Medicine (NASDAQ: CMND). As part of the collaboration, three U...

September 24, 2026

Developments

MAIA expands pivotal Phase 3 study of THIO-104 in NSCLC

MAIA Biotechnology (NYSE American: MAIA) has received regulatory approval by the Spanish Agency for Medicines and Medical Devices and Portugal’s National Authority of Medicines and Health Products to begin...

September 24, 2026

Executive Moves

Valion appoints life sciences veteran Dean Zikria as interim CEO and announces board leadership transitions

Valion Bio (NASDAQ: VBIO) has announced the appointment of Dean Zikria as interim CEO, along with leadership changes aimed at strengthening alignment and execution as it advances Entolimod and evaluates strategic...

September 24, 2026

Developments

Medicus to focus SkinJect on Gorlin syndrome patients

Medicus Pharma (NASDAQ: MDCX) has announced it will focus SkinJect development exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and will conclude further development in sporadic/nodular...

September 22, 2026

Developments

Profound Medical’s new president makes open market purchase of company shares

According to a filing with SEDI, Profound Medical (NASDAQ:PROF; TSX:PRN) president, Richard Fabian, acquired a total of 10,000 shares of Profound on the open market today at a cost of $59,800 (U.S.). In a sign of...

September 17, 2026

Developments

Xenetic and Santersus enter into definitive share exchange agreement

Xenetic Biosciences (NASDAQ: XBIO) has entered into a definitive share exchange agreement to acquire closely held Santersus in an all-stock transaction, subject to stockholder approval. The combined company is expected...

September 17, 2026

Developments

BioPorto initiates patient enrollment in adult urine NGAL validation study

BioPorto (CPH: BIOPOR) has announced the enrollment of the first patient as part of the ProNephro AKI U.S. Adult Urine NGAL Validation Study, marking an important milestone in the company’s clinical efforts to...

September 17, 2026

Subscribe